Enliven Therapeutics's three largest insider shareholders as of September 29, 2026 are Advisors Llc Orbimed (Director, 8.66Mn shares), Rishi Gupta (Director, 8.66Mn shares), Rishi Gupta (Director, 7.66Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Rishi Gupta | Director, TenPercentOwner | 0 | 7,663,349 | 7,663,349 | 35.7% | 20 May, 2024 |
| 2 | Advisors Llc Orbimed | TenPercentOwner | 0 | 6,555,102 | 6,555,102 | 30.6% | 22 Jun, 2026 |
| 3 | Partners Vi, Llc 5Am | TenPercentOwner | 0 | 3,835,975 | 3,835,975 | 17.9% | 16 Feb, 2024 |
| 4 | Samuel Kintz | President And Ceo | 0 | 890,392 | 890,392 | 4.1% | 19 Nov, 2025 |
| 5 | Enterprise Associates 14, L.P. New | TenPercentOwner | 652,763 | 0 | 652,763 | 3.0% | 07 Apr, 2022 |
| 6 | Capital Management, L.P. Ra | Other | 0 | 530,616 | 530,616 | 2.5% | 27 Feb, 2023 |
| 7 | Braden Michael Leonard | TenPercentOwner | 0 | 441,944 | 441,944 | 2.1% | 05 Jan, 2023 |
| 8 | Capital Lp Commodore | TenPercentOwner | 0 | 362,160 | 362,160 | 1.7% | 27 Feb, 2023 |
| 9 | Andrew J. Schwab | Director | 0 | 240,096 | 240,096 | 1.1% | 27 Feb, 2023 |
| 10 | David M Mott | Director | 57,306 | 0 | 57,306 | 0.3% | 23 Feb, 2022 |
| 11 | Lori Anne Kunkel | Director | 41,884 | 0 | 41,884 | 0.2% | 08 Jul, 2026 |
| 12 | Benjamin Hohl | Chief Financial Officer | 38,000 | 0 | 38,000 | 0.2% | 21 Sep, 2026 |
| 13 | Helen Louise Collins | Chief Medical Officer | 25,000 | 0 | 25,000 | 0.1% | 21 Sep, 2026 |
| 14 | Richard A. Heyman | Director | 0 | 22,647 | 22,647 | 0.1% | 19 Feb, 2026 |
| 15 | Rahul D. Ballal | Chief Executive Officer | 22,341 | 0 | 22,341 | 0.1% | 10 Oct, 2024 |
| 16 | Jake Bauer | Director | 21,843 | 0 | 21,843 | 0.1% | 27 Feb, 2023 |
| 17 | Anish Patel | Chief Operating Officer | 20,000 | 0 | 20,000 | 0.1% | 17 Feb, 2026 |
| 18 | Joseph P Lyssikatos | Chief Scientific Officer | 18,750 | 0 | 18,750 | 0.1% | 17 Feb, 2026 |
| 19 | Kenneth Attie | Svp, Cmo | 8,525 | 0 | 8,525 | 0.0% | 01 Feb, 2022 |
| 20 | Michael Gray | Cfo Coo | 6,903 | 0 | 6,903 | 0.0% | 22 Feb, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 17 Sep, 2026 | Helen Louise Collins | Chief Medical Officer | Acquired M | 5,000 | $2.48 | $12.40K | 30,000 | Direct |
| 17 Sep, 2026 | Benjamin Hohl | Chief Financial Officer | Acquired M | 3,982 | $14.85 | $59.13K | 44,018 | Direct |
| 17 Sep, 2026 | Benjamin Hohl | Chief Financial Officer | Disposed S | 3,535 | $50.03 | $176.85K | 40,483 | Direct |
| 17 Sep, 2026 | Helen Louise Collins | Chief Medical Officer | Disposed S | 2,916 | $50.03 | $145.89K | 27,084 | Direct |
| 17 Sep, 2026 | Helen Louise Collins | Chief Medical Officer | Disposed S | 1,844 | $50.71 | $93.51K | 25,240 | Direct |
| 17 Sep, 2026 | Benjamin Hohl | Chief Financial Officer | Disposed S | 2,194 | $50.72 | $111.27K | 38,289 | Direct |
| 17 Sep, 2026 | Helen Louise Collins | Chief Medical Officer | Disposed S | 240 | $51.48 | $12.36K | 25,000 | Direct |
| 17 Sep, 2026 | Benjamin Hohl | Chief Financial Officer | Disposed S | 289 | $51.49 | $14.88K | 38,000 | Direct |
| 17 Sep, 2026 | Benjamin Hohl | Chief Financial Officer | Disposed M | 3,982 | $0.00 | $0 | 181,018 | Direct |
| 17 Sep, 2026 | Helen Louise Collins | Chief Medical Officer | Disposed M | 5,000 | $0.00 | $0 | 106,268 | Direct |
| 17 Aug, 2026 | Benjamin Hohl | Chief Financial Officer | Disposed S | 4,630 | $58.35 | $270.17K | 41,424 | Direct |
| 17 Aug, 2026 | Helen Louise Collins | Chief Medical Officer | Acquired M | 5,000 | $2.48 | $12.40K | 30,000 | Direct |
| 17 Aug, 2026 | Helen Louise Collins | Chief Medical Officer | Disposed S | 3,900 | $58.37 | $227.65K | 26,100 | Direct |
| 17 Aug, 2026 | Benjamin Hohl | Chief Financial Officer | Disposed S | 1,388 | $59.35 | $82.38K | 40,036 | Direct |
| 17 Aug, 2026 | Helen Louise Collins | Chief Medical Officer | Disposed S | 1,100 | $59.35 | $65.28K | 25,000 | Direct |
| 17 Aug, 2026 | Helen Louise Collins | Chief Medical Officer | Disposed M | 5,000 | $0.00 | $0 | 111,268 | Direct |
| 04 Aug, 2026 | Mika K Derynck | Director | Acquired M | 87,373 | $2.48 | $216.69K | 87,373 | Direct |
| 04 Aug, 2026 | Mika K Derynck | Director | Acquired M | 27,567 | $25.28 | $696.89K | 114,940 | Direct |
| 04 Aug, 2026 | Mika K Derynck | Director | Acquired M | 23,364 | $14.85 | $346.96K | 138,304 | Direct |
| 04 Aug, 2026 | Mika K Derynck | Director | Acquired M | 20,491 | $22.47 | $460.43K | 158,795 | Direct |